Significantly more patients achieved their secondary passive goal with onabotulinumtoxinA + standard of care ( 60.0 % ) vs. placebo + standard of care ( 38.6 % ) ( odds ratio , 2.46 ; 95 % confidence interval , 1.18-5 .14 ) as well as higher Goal Attainment Scaling levels for upper limb and ankle flexor subgroups .